LenioBio GmbH
LenioBio GmbH develops scalable eukaryotic cell-free protein expression technologies enabling rapid and flexible production of complex proteins. Its proprietary platform facilitates expression of membrane proteins, antibodies, virus-like particles, and proteins with complex post-translational modifications, supporting applications from research to biomanufacturing and vaccine development. The technology addresses key bottlenecks in traditional protein production, offering fast turnaround, batch consistency, and the potential for integration with rapid DNA template synthesis. LenioBio collaborates with leading industry partners and continually advances its platform for broad accessibility and application in life sciences.
Industries
Nr. of Employees
small (1-50)
LenioBio GmbH
LenioBio GmbH, Merowingerplatz 1a, 40225 Dusseldorf, Germany
Products
Cell-free protein expression research kit (Maxi Kit)
Kit providing plant cell lysate for high-yield protein expression, supports complex post-translational modifications and up to 60 reactions.
Cell-free protein expression research kit (Midi Kit)
Kit for small to mid-scale protein expression experiments, optimized for high yield and complex modifications.
Cell-free protein expression Scale-Up kit (5 mL, 10 mL, large volume)
Protein production kit designed for mg- to multi-gram scale using scalable plant cell lysate systems, supports up to 10 L scale with consistent yield.
High-throughput protein expression screening kits
Products and protocols designed for rapid antibody and protein candidate screening using cell-free systems, suitable for automation in high-throughput formats.
Cell-free protein expression feasibility and development packages
Service offerings for feasibility assessment, screening, development, and scalable production of research-grade proteins using cell-free technology.
Cell-free protein expression research kit (Maxi Kit)
Kit providing plant cell lysate for high-yield protein expression, supports complex post-translational modifications and up to 60 reactions.
Cell-free protein expression research kit (Midi Kit)
Kit for small to mid-scale protein expression experiments, optimized for high yield and complex modifications.
Cell-free protein expression Scale-Up kit (5 mL, 10 mL, large volume)
Protein production kit designed for mg- to multi-gram scale using scalable plant cell lysate systems, supports up to 10 L scale with consistent yield.
High-throughput protein expression screening kits
Products and protocols designed for rapid antibody and protein candidate screening using cell-free systems, suitable for automation in high-throughput formats.
Cell-free protein expression feasibility and development packages
Service offerings for feasibility assessment, screening, development, and scalable production of research-grade proteins using cell-free technology.
Services
Provides tailored protein production services using cell-free expression, covering cloning, optimization, expression, and purification for diverse targets, including membrane proteins and antibodies.
Provides tailored protein production services using cell-free expression, covering cloning, optimization, expression, and purification for diverse targets, including membrane proteins and antibodies.
Expertise Areas
- Cell-free protein expression platforms
- Production of eukaryotic proteins including membrane proteins and antibodies
- High-throughput protein and antibody screening
- Scale-up of biomanufacturing processes
Key Technologies
- Eukaryotic cell-free protein expression
- Plant cell lysate-based synthesis
- Microsome-supported post-translational modification
- Expression of membrane proteins and antibodies
News & Updates
Announced collaboration with Touchlight to integrate rapid enzymatic DNA synthesis with cell-free protein expression platforms for accelerated vaccine and therapeutic protein development, as part of a CEPI-funded initiative.
Engaged Avantor as a distribution partner to increase accessibility of cell-free protein expression solutions across Europe.
Appointed André Goerke as Chief Executive Officer, succeeding founder Dr. Remberto Martis.
Entered collaboration with ReciBioPharm to scale up cell-free protein expression to GMP-relevant and clinical-trial scale, as part of CEPI's 100 Days Mission.
Established strategic partnership with Labscoop to improve accessibility to cell-free protein expression technologies in North America.
Secured exclusive license agreement with Fraunhofer IME for vector and cryopreservation technology optimized for cell-free expression.
Announced collaboration with Touchlight to integrate rapid enzymatic DNA synthesis with cell-free protein expression platforms for accelerated vaccine and therapeutic protein development, as part of a CEPI-funded initiative.
Engaged Avantor as a distribution partner to increase accessibility of cell-free protein expression solutions across Europe.
Appointed André Goerke as Chief Executive Officer, succeeding founder Dr. Remberto Martis.
Entered collaboration with ReciBioPharm to scale up cell-free protein expression to GMP-relevant and clinical-trial scale, as part of CEPI's 100 Days Mission.
Established strategic partnership with Labscoop to improve accessibility to cell-free protein expression technologies in North America.
Secured exclusive license agreement with Fraunhofer IME for vector and cryopreservation technology optimized for cell-free expression.